Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of an Adenovirus-Based Tuberculosis Vaccine.
Phase of Trial: Phase I
Latest Information Update: 05 Jul 2017
At a glance
- Drugs Tuberculosis DNA vaccine Ag85A (Primary)
- Indications Tuberculosis
- Focus Adverse reactions
- 01 Jul 2013 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
- 03 Oct 2011 Planned End Date changed from 1 Jul 2011 to 1 Jul 2012 as reported by ClinicalTrials.gov.
- 22 Jul 2010 Planned end date changed from 1 Dec 2010 to 1 Jul 2011 as reported by ClinicalTrials.gov.